<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603835</url>
  </required_header>
  <id_info>
    <org_study_id>IDE G120029/S007</org_study_id>
    <nct_id>NCT02603835</nct_id>
  </id_info>
  <brief_title>Evaluation of Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients (IC-HOT)</brief_title>
  <acronym>IC-HOT</acronym>
  <official_title>A Multi-Center Evaluation of the Delivery of Intracoronary Hyperoxemic Supersaturated Oxygen Therapy for 60 Minutes in Anterior Acute Myocardial Infarction Patients With Successful Reperfusion (Via PCI) ≤ Six Hours After Symptom Onset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TherOx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TherOx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to collect confirmatory data supporting the safety and
      effectiveness of SSO2 Therapy in treatment of anterior acute myocardial infarction (AMI)
      patients who have undergone successful percutaneous coronary intervention (PCI) with stenting
      within six hours of experiencing AMI symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multi-Center, Consecutively Enrolled Single-Arm Study to confirm the safety and
      effectiveness of the delivery of supersaturated oxygen (SSO2) Therapy for 60 minutes
      selectively into the left main coronary artery (LMCA) with a commercially available qualified
      SSO2 delivery catheter used with the TherOx® DownStream® System and Cartridge in the
      treatment of qualified patients presenting with anterior acute myocardial infarction in whom
      reperfusion with PCI is successful within six hours after symptom onset.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net Adverse Clinical Events (NACE)</measure>
    <time_frame>30-Day</time_frame>
    <description>Composite of death, reinfarction, clinically-driven target vessel revascularization, stent thrombosis (ARC definite or probable), new onset severe heart failure or readmission for heart failure, and TIMI major or minor bleeding</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Anterior Wall Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>SSO2 Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SSO2 Therapy</intervention_name>
    <description>Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter</description>
    <arm_group_label>SSO2 Therapy</arm_group_label>
    <other_name>TherOx DownStream System</other_name>
    <other_name>TherOx DownStream Cartridge</other_name>
    <other_name>SSO2 Delivery Catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        GENERAL INCLUSION CRITERIA: Candidates for this study must meet ALL of the following
        criteria:

        Pre-PCI:

          1. The subject must be ≥18 and ≤80 years of age.

          2. AMI must be anterior (ST-segment elevation &gt;1 mm in two or more contiguous leads
             between V1 and V4 or new left bundle branch block).

          3. Subject is experiencing clinical symptoms consistent with anterior AMI of ≤6 hour
             duration from time of symptom onset until admission to the emergency room.

          4. The subject or legally authorized representative has been informed of the nature of
             the study, agrees to its provisions and has been provided and signed written informed
             consent, approved by the appropriate Institutional Review Board (IRB).

          5. Subject and his/her physician agree to all required follow-up procedures and visits.

             ANGIOGRAPHIC INCLUSION CRITERIA: These are evaluated after the subject has provided
             signed informed consent but prior to enrollment:

          6. Based on coronary anatomy, PCI is indicated for revascularization of the culprit
             lesion(s) with use of a commercially available coronary stent (bare metal or
             drug-eluting, at operator discretion) in the LAD.

          7. The primary stented infarct-related lesion(s) must be in the proximal and/or mid-LAD
             coronary artery (other lesions in the LAD target vessel, including diagonal branches,
             may be treated if clinically indicated).

          8. Baseline (pre-PCI) TIMI flow grade 0, 1, 2, or 3 flow in the LAD.

          9. Successful angioplasty as documented by &lt;50% diameter residual angiographic stenosis
             within all treated culprit lesions with TIMI 2 or 3 flow and no major complications
             such as perforation or shock.

         10. Expected ability to place the SSO2 delivery catheter in the coronary ostium of the
             left main coronary system to deliver SSO2 Therapy with stable, coaxial alignment.

        GENERAL EXCLUSION CRITERIA:

        Pre-PCI:

          1. Prior CABG surgery.

          2. Prior myocardial infarction, or known prior systolic dysfunction (known ejection
             fraction &lt;40% by any prior measure or regional wall motion abnormalities; this
             criterion does not include left ventricular dysfunction induced by the acute MI).

          3. Thrombolytic therapy administered for this STEMI.

          4. An elective surgical procedure is planned that would necessitate interruption of
             anti-platelet agents during the first 30 days post-enrollment.

          5. Subjects who previously underwent coronary stent implantation and in whom coronary
             angiography demonstrates stent thrombosis to be the cause of the anterior AMI.

          6. Subjects who have previously undergone an angioplasty or stenting procedure in the
             left anterior descending coronary artery.

          7. Subjects with ventricular pseudoaneurysm, VSD, or severe mitral valve regurgitation
             (with or without papillary muscle rupture).

          8. Any contraindication to MRI imaging. This will include any of the following
             exclusions:

               -  Cardiac pacemaker or implantable defibrillator;

               -  Non-MRI compatible aneurysm clip;

               -  Neural Stimulator (i.e., TENS unit);

               -  Any implanted or magnetically activated device (insulin pump);

               -  Any type of non-MRI compatible ear implant;

               -  Metal shavings in the orbits;

               -  Any metallic foreign body, shrapnel, or bullet in a location which the physician
                  feels would present a risk to the subject;

               -  Any history indicating contraindication to MRI, including claustrophobia or
                  allergy to gadolinium;

               -  Inability to follow breath hold instructions or to maintain a breath hold for &gt;15
                  seconds; and

               -  Known hypersensitivity or contraindication to gadolinium contrast.

          9. Known impaired renal function (creatinine clearance &lt;30 ml/min/1.73 m2

         10. Known platelet count &lt;100,000 cells/mm by the MDRD formula) or on dialysis. 3 or
             &gt;700,000 cells/mm3

         11. Subject has active bleeding or a history of bleeding diathesis or coagulopathy
             (including heparin induced thrombocytopenia), or refusal to receive blood transfusions
             if necessary. or a known Hgb &lt;10 g/dL.

         12. History of intracerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic
             stroke.

         13. Stroke or transient ischemic attack within the past six (6) months, or any permanent
             neurological defect.

         14. Gastrointestinal or genitourinary bleeding within the last two (2) months, or any
             major surgery (including CABG) within six weeks of enrollment.

         15. Subject has received any organ transplant or is on a waiting list for any organ
             transplant.

         16. Subject has other medical illness (e.g., cancer, dementia) or known history of
             substance abuse (alcohol, cocaine, heroin, etc.) that may cause non-compliance with
             the protocol, confound the data interpretation, or is associated with limited life
             expectancy of less than one year.

         17. Subject has a known hypersensitivity or contraindication to unfractionated heparin,
             abciximab, aspirin, bivalirudin, cangrelor, clopidogrel, ticlopidine, prasugrel, or
             ticagrelor that cannot be adequately premeditated.

         18. Current use of warfarin, dabigatran, or factor Xa inhibitors, or known intent to
             administer these agents after the primary PCI.

         19. Subjects presenting with or developing in the cath lab prior to completion of the
             primary PCI procedure any of the following conditions: cardiogenic shock (SBP &lt;80 mmHg
             for &gt;30 minutes), or requiring IV pressors or emergent placement of an intra-aortic
             balloon pump (IABP), Impella, or other hemodynamic support for hypotension treatment,
             or cardiopulmonary resuscitation for &gt;10 minutes, or ventricular fibrillation or
             tachycardia requiring cardioversion or defibrillation.

         20. Severe known cardiac valvular stenosis or insufficiency, pericardial disease, or
             non-ischemic cardiomyopathy.

         21. Any significant medical or social condition which in the investigator's opinion may
             interfere with the subject's participation in the study or ability to comply with
             follow-up procedures, including MRI (e.g. alcoholism, dementia, lives far from the
             research center, etc.).

         22. Current participation in other investigational device or drug trials that have not
             finished the primary endpoint follow-up period.

         23. Previous enrollment in this study.

             ANGIOGRAPHIC EXCLUSION CRITERIA: These are evaluated after the subject has provided
             signed Informed Consent but prior to enrollment:

         24. Anticipated inability to achieve a stable coaxial position in the left main coronary
             artery with the SSO2 delivery catheter.

         25. Treatment during the index procedure of any lesion in either the left main, LCX
             (including the ramus), and/or RCA.

         26. Post-index procedure planned intervention within 30 days (i.e., PCI of non-target
             lesions in any vessel, or CABG). Note: Planned revascularization (PCI or bypass) of a
             non-target lesion &gt;30 days following the index procedure is allowed.

         27. Anterior MI is due to thrombosis within or adjacent to a previously implanted stent.

         28. Left ventriculography demonstrates severe mitral regurgitation, a ventricular septal
             defect, or a pseudoaneurysm.

         29. Any left main coronary artery stenosis &gt;20%.

         30. Any untreated LAD or diagonal branch lesion is present with diameter stenosis &gt; 50% in
             a vessel with reference vessel diameter &gt; 2.0 mm (visually estimated), or for which
             PCI will be required before the MRI study.

         31. Presence of a non-stented coronary dissection with NHLBI grade &gt;B upon completion of
             the PCI procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregg W. Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Center, Inc.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danbury Hospital</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Heart &amp; Vascular Institute</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Hospital &amp; Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence-Providence Park Hospital</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WakeMed Heart Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Spirit Cardiology</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital/Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont CVA Heart Institute</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SSO2 Therapy</keyword>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Anterior myocardial infarction</keyword>
  <keyword>SuperSaturated oxygen delivery</keyword>
  <keyword>Left main coronary artery</keyword>
  <keyword>Myocardial infarction</keyword>
  <keyword>Heart attack</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Cardiac catheterization laboratory</keyword>
  <keyword>PCI</keyword>
  <keyword>Stent</keyword>
  <keyword>Stenting</keyword>
  <keyword>Stents</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>LMCA</keyword>
  <keyword>Delivery of supersaturated oxygen (SSO2) therapy for the treatment of anterior acute myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

